News & Events
Dr. Barrett Introduces Patients to Leading Cornea Treatment Technology
Dr. Ryan Barrett is the only eye surgeons in the area to specialize in FDA-approved corneal collagen cross-linking. This procedure is the first therapeutic treatment that has been rigorously tested and FDA-approved for keratoconus and other forms of corneal ectasia. Designed to strengthen and stabilize the weakened links bonding the corneal fibers together, corneal cross-linking preserves vision quality and is 92-97% effective at preventing future progression of keratoconus.
Maria R., another happy patient with the results of crosslinking.
Now Offering iStent for Patients with Cataracts & Glaucoma
For patients dealing with both cataracts and glaucoma, Hollingshead Eye Center offers state-of-the-art MIGS technology. MIGS includes microsurgical implants that can be placed in the eye at the time of cataract surgery to decrease eye pressure and thus decrease the need for glaucoma drops or the risk of vision loss from glaucoma. MIGS devices include the iStent inject, the world’s smallest medical implant, and the Hydrus. These are designed to lower eye pressure by improving the eye’s natural fluid outflow and may be inserted during cataract surgery. Covered by Medicare and most private insurance plans, MIGS is a convenient way to receive treatment for both eye conditions simultaneously. It may also reduce reliance on glaucoma medication.
During August Hollingshead Eye Center Observes Cataract Awareness Month
Dr. Mark Hollingshead of Hollingshead Eye Center expects to be handling more questions about what a cataract is - and explaining what it is not during Cataract Awareness Month. Read the full press release.
Hollingshead Eye Center Acquires Optos Imaging Technology
Hollingshead Eye Center has acquired recently-introduced imaging technology that makes it possible to diagnose, analyze, and monitor conditions that may have otherwise gone undetected. It also provides a digital record that is particularly useful in monitoring the progression of these conditions.
“Optos 200Tx-AF® ultra-widefield imaging technology has been designed specifically for ophthalmologists and vitreoretinal specialists,” said Dr. Mark Hollingshead. “The typical manual technique for examining the retina reveals only 10 to 12 percent of it at one time. The 200Tx-AF provides a panoramic map of more than 80 percent of the retina and gives us a new avenue of information that we haven’t had until now.”
That wide, edge-to-edge view enhances an ophthalmologist’s ability to detect the earliest signs of retinal diseases, such as diabetic retinopathy and macular degeneration.
“Our continuing investment in technology gives my patients access to state-of-the-art treatment,” said Hollingshead. “When we can see more, we can do more.”